Cargando…

Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans

BACKGROUND: Glutamate transmission is implicated in drug-induced behavioural sensitization and the associated long-lasting increases in mesolimbic output. Metabotropic glutamate type 5 (mGlu5) receptors might be particularly important, but most details are poorly understood. METHODS: We first assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Smart, Kelly, Nagano-Saito, Atsuko, Milella, Michele S., Sakae, Diana Yae, Favier, Mathieu, Vigneault, Erika, Louie, Leanne, Hamilton, Alison, Ferguson, Stephen S.G., Rosa-Neto, Pedro, Narayanan, Sridar, Mestikawy, Salah El, Leyton, Marco, Benkelfat, Chawki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Joule Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955855/
https://www.ncbi.nlm.nih.gov/pubmed/32559027
http://dx.doi.org/10.1503/jpn.190162
_version_ 1783664328616968192
author Smart, Kelly
Nagano-Saito, Atsuko
Milella, Michele S.
Sakae, Diana Yae
Favier, Mathieu
Vigneault, Erika
Louie, Leanne
Hamilton, Alison
Ferguson, Stephen S.G.
Rosa-Neto, Pedro
Narayanan, Sridar
Mestikawy, Salah El
Leyton, Marco
Benkelfat, Chawki
author_facet Smart, Kelly
Nagano-Saito, Atsuko
Milella, Michele S.
Sakae, Diana Yae
Favier, Mathieu
Vigneault, Erika
Louie, Leanne
Hamilton, Alison
Ferguson, Stephen S.G.
Rosa-Neto, Pedro
Narayanan, Sridar
Mestikawy, Salah El
Leyton, Marco
Benkelfat, Chawki
author_sort Smart, Kelly
collection PubMed
description BACKGROUND: Glutamate transmission is implicated in drug-induced behavioural sensitization and the associated long-lasting increases in mesolimbic output. Metabotropic glutamate type 5 (mGlu5) receptors might be particularly important, but most details are poorly understood. METHODS: We first assessed in mice (n = 51, all male) the effects of repeated dextroamphetamine administration (2.0 mg/kg, i.p.) on locomotor activity and binding of the mGlu5 ligand [(3)H]ABP688. In a parallel study, in 19 stimulant-drug-naïve healthy human volunteers (14 female) we administered 3 doses of dextroamphetamine (0.3 mg/kg, p.o.) or placebo, followed by a fourth dose 2 weeks later. We measured [(11)C]ABP688 binding using positron emission tomography before and after the induction phase. We assessed psychomotor and behavioural sensitization using speech rate, eye blink rate and self-report. We measured the localization of mGlu5 relative to synaptic markers in mouse striatum using immunofluorescence. RESULTS: We observed amphetamine-induced psychomotor sensitization in mice and humans. We did not see group differences in mGlu5 availability following 3 pre-challenge amphetamine doses, but group differences did develop in mice administered 5 doses. In mice and humans, individual differences in mGlu5 binding after repeated amphetamine administration were negatively correlated with the extent of behavioural sensitization. In drug-naïve mice, mGlu5 was expressed at 67% of excitatory synapses on dendrites of striatal medium spiny neurons. LIMITATIONS: Correlational results should be interpreted as suggestive because of the limited sample size. We did not assess sex differences. CONCLUSION: Together, these results suggest that changes in mGlu5 availability are not part of the earliest neural adaptations in stimulant-induced behavioural sensitization, but low mGlu5 binding might identify a higher propensity for sensitization.
format Online
Article
Text
id pubmed-7955855
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Joule Inc.
record_format MEDLINE/PubMed
spelling pubmed-79558552021-03-19 Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans Smart, Kelly Nagano-Saito, Atsuko Milella, Michele S. Sakae, Diana Yae Favier, Mathieu Vigneault, Erika Louie, Leanne Hamilton, Alison Ferguson, Stephen S.G. Rosa-Neto, Pedro Narayanan, Sridar Mestikawy, Salah El Leyton, Marco Benkelfat, Chawki J Psychiatry Neurosci Research Paper BACKGROUND: Glutamate transmission is implicated in drug-induced behavioural sensitization and the associated long-lasting increases in mesolimbic output. Metabotropic glutamate type 5 (mGlu5) receptors might be particularly important, but most details are poorly understood. METHODS: We first assessed in mice (n = 51, all male) the effects of repeated dextroamphetamine administration (2.0 mg/kg, i.p.) on locomotor activity and binding of the mGlu5 ligand [(3)H]ABP688. In a parallel study, in 19 stimulant-drug-naïve healthy human volunteers (14 female) we administered 3 doses of dextroamphetamine (0.3 mg/kg, p.o.) or placebo, followed by a fourth dose 2 weeks later. We measured [(11)C]ABP688 binding using positron emission tomography before and after the induction phase. We assessed psychomotor and behavioural sensitization using speech rate, eye blink rate and self-report. We measured the localization of mGlu5 relative to synaptic markers in mouse striatum using immunofluorescence. RESULTS: We observed amphetamine-induced psychomotor sensitization in mice and humans. We did not see group differences in mGlu5 availability following 3 pre-challenge amphetamine doses, but group differences did develop in mice administered 5 doses. In mice and humans, individual differences in mGlu5 binding after repeated amphetamine administration were negatively correlated with the extent of behavioural sensitization. In drug-naïve mice, mGlu5 was expressed at 67% of excitatory synapses on dendrites of striatal medium spiny neurons. LIMITATIONS: Correlational results should be interpreted as suggestive because of the limited sample size. We did not assess sex differences. CONCLUSION: Together, these results suggest that changes in mGlu5 availability are not part of the earliest neural adaptations in stimulant-induced behavioural sensitization, but low mGlu5 binding might identify a higher propensity for sensitization. Joule Inc. 2021-01 2020-06-19 /pmc/articles/PMC7955855/ /pubmed/32559027 http://dx.doi.org/10.1503/jpn.190162 Text en © 2021 Joule Inc. or its licensors This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is non-commercial (i.e. research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Research Paper
Smart, Kelly
Nagano-Saito, Atsuko
Milella, Michele S.
Sakae, Diana Yae
Favier, Mathieu
Vigneault, Erika
Louie, Leanne
Hamilton, Alison
Ferguson, Stephen S.G.
Rosa-Neto, Pedro
Narayanan, Sridar
Mestikawy, Salah El
Leyton, Marco
Benkelfat, Chawki
Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans
title Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans
title_full Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans
title_fullStr Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans
title_full_unstemmed Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans
title_short Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans
title_sort metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955855/
https://www.ncbi.nlm.nih.gov/pubmed/32559027
http://dx.doi.org/10.1503/jpn.190162
work_keys_str_mv AT smartkelly metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT naganosaitoatsuko metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT milellamicheles metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT sakaedianayae metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT faviermathieu metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT vigneaulterika metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT louieleanne metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT hamiltonalison metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT fergusonstephensg metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT rosanetopedro metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT narayanansridar metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT mestikawysalahel metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT leytonmarco metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans
AT benkelfatchawki metabotropicglutamatetype5receptorbindingavailabilityduringdextroamphetaminesensitizationinmiceandhumans